1 / 33

C Loprinzi P Atherton R Qin D Seisler S Dakhil R Qamar

Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity, N08CB An Alliance for Clinical Trials in Oncology Study. C Loprinzi P Atherton R Qin D Seisler S Dakhil R Qamar

hamish
Download Presentation

C Loprinzi P Atherton R Qin D Seisler S Dakhil R Qamar

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity, N08CB An Alliance for Clinical Trials in Oncology Study C Loprinzi P Atherton R Qin D Seisler S Dakhil R Qamar L Fehrenbacher G LewisP Stella A Grothey

  2. There are no relevant financial relationships to disclose

  3. Background • Neurologic symptoms are a major oxaliplatin-induced toxicity • Acute neuropathy • Chronic peripheral neurotoxicity-dose limiting • Improves after drug cessation in many • Prominent chronic neurotoxicity in some • Treatment options are limited

  4. Background • Finding an effective and safe way to prevent the neuropathy…. • In a retrospective, non-randomized study, intravenous administration of CaMg was associated with reduced oxaliplatin-induced neuropathy (Gamelin, Clin Cancer Res 2004) • Subsequent randomized trials • Prematurely stopped due to an errant DMC report • Revealed mixed results

  5. IV CaMg IV placebo N04C7 Cancer Control Phase III Trial – Study Design Patients to receive adj FOLFOX R % of grade 2+ sNT Grothey et al; J Clin Oncol 2011; 29(4):421-7 CP1347589-5

  6. Primary endpoint Grade 2+ sNT (CTCAE Scale) CP1347589-6

  7. Time to Grade 2+ sNT (CTC scale) Ca/Mg % Free 2+ sNT Placebo P=0.05 Weeks CP1347589-7

  8. Background Current trial designed to provide a definitive answer

  9. Key Inclusion Criteria • Age >18 years • Resected adenocarcinoma of the colon • No evidence of residual disease • Scheduled to receive 12 cycles of oxaliplatin-based adjuvant chemotherapy with 85 mg/m2 oxaliplatin every 2 weeks • No pre-existing peripheral neuropathy of any grade or neurotoxic chemotherapy

  10. Total Accrual: 362 Patients Cancels: 6 Ineligibles: 3 Arm A: CaMg before and after chemo Baseline: 118 patients Arm B: Placebo before and after chemo Baseline: 119 patients Arm C: CaMg before chemo and placebo after chemo Baseline: 116 patients Primary endpoint: 110 Primary endpoint: 106 Primary endpoint: 110 Double-blinded

  11. Neurotoxicity Evaluation- Chronic • EORTC QLQ-CIPN20 sensory sub-scale • Oxaliplatin-specific neuropathy instrument • NCI-CTCAE-version 4.0

  12. Neuropathy Evaluation-Acute

  13. Neuropathy Evaluation-Acute

  14. Statistics Primary endpoint • The area under the curve (AUC) of CIPN20 sensory scale during the 12 cycles of chemotherapy • Wilcoxon rank-sum test was used • Bonferroni adjustment for two comparisons

  15. Statistics • A sample size of 107 patients, per arm provided 80% power • To detect a difference in incidence of grade 2+ neuropathic toxicity from • 40% in the placebo arm to • 20% in either schedule of the CaMg infusion arms

  16. Results

  17. Pertinent patient characteristics

  18. Pertinent patient characteristics

  19. Adverse Events • No substantial differences between CaMg and Placebo in any recorded adverse events

  20. Chronic Neuropathy

  21. Sensory Neuropathy by Treatment Arm Mean score (0-100 scale) Cycle n= CaMg/CaMg 114 108 103 103 97 88 89 84 76 73 58 46 Placebo/Placebo 111 105 104 104 95 92 82 81 71 66 52 40 CaMg/Placebo 112 105 109 105 95 99 94 85 80 71 59 51

  22. Time to Grade 2 Neuropathy 100 90 80 70 60 50 40 30 20 10 0 Without Grade 2 neuropathy (% of patients) P=0.3383 0 1 2 3 4 5 6 7 8 9 10 11 12 Cycle n= CaMg/CaMg 109 109 106 100 95 85 77 68 63 60 54 47 26 Placebo/Placebo 105 104 103 94 90 81 75 67 59 54 49 46 22 CaMg/Placebo 108 107 101 96 93 87 77 72 69 62 58 53 29

  23. Time to Grade 2 Oxaliplatin — Induced Neuropathy 100 90 80 70 60 50 40 30 20 10 0 Without Grade 2 neuropathy (% of patients) P=0.9721 0 1 2 3 4 5 6 7 8 9 10 11 12 Cycle n= CaMg/CaMg 110 110 107 99 90 76 67 58 47 43 39 35 19 Placebo/Placebo 107 106 103 93 84 78 70 63 56 48 41 37 18 CaMg/Placebo 111 108 101 94 89 77 65 61 55 46 40 36 13

  24. Acute Neuropathy

  25. Sensitivity to Touching Cold Items 10 9 8 7 6 5 4 3 2 1 0 Mean score (0-10 scale) P=0.7978 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 Cycle 9 Cycle 10 Cycle 11 Cycle 12 Days n= CaMg/CaMg 112 106 99 97 92 89 85 79 72 69 54 41 Placebo/Placebo 109 100 100 96 92 87 82 69 68 65 45 40 CaMg/Placebo 110 103 100 99 93 95 89 82 77 64 60 49

  26. Discomfort Swallowing Cold Liquids 10 9 8 7 6 5 4 3 2 1 0 Mean score (0-10 scale) P=0.4274 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 Cycle 9 Cycle 10 Cycle 11 Cycle 12 Days n= CaMg/CaMg 112 104 97 97 91 87 84 77 71 68 52 40 Placebo/Placebo 109 99 99 95 90 86 81 68 67 64 44 39 CaMg/Placebo 110 103 100 98 93 95 88 82 77 64 60 49

  27. Throat Discomfort 10 9 8 7 6 5 4 3 2 1 0 Mean score (0-10 scale) P=0.0366 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 Cycle 9 Cycle 10 Cycle 11 Cycle 12 Days n= CaMg/CaMg 112 106 99 97 92 89 85 79 73 69 54 41 Placebo/Placebo 109 99 101 96 93 88 82 70 69 65 46 40 CaMg/Placebo 110 103 101 99 93 96 89 82 77 64 60 49

  28. Muscle Cramps 10 9 8 7 6 5 4 3 2 1 0 Mean score (0-10 scale) P=0.5501 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 Cycle 9 Cycle 10 Cycle 11 Cycle 12 Days n= CaMg/CaMg 112 106 99 97 92 89 85 79 73 69 54 41 Placebo/Placebo 109 100 101 96 93 86 82 70 69 63 46 40 CaMg/Placebo 110 103 101 99 93 96 89 82 77 64 60 49

  29. Effect on Oxaliplatin Doses

  30. Oxaliplatin Use Based on Rx Arm Patients receiving Oxaliplatin (%) P=0.62 Cycle

  31. % of Patients Receiving Full Dose of Oxaliplatin by Rx Arm Receiving full dose (% of patients) P=0.25 Cycle

  32. Average Oxaliplatin Dose (mg/m2) by Rx Arm Oxaliplatin dose (mg/m2) P=0.11 Cycle

  33. Conclusion • The data from this well-powered clinical trial did not support the use of intravenous CaMg use for preventing Oxaliplatin-induced neuropathy

More Related